CellCentric Ltd.: Clinical Trials

3 trials sponsored by CellCentric Ltd., newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 recruiting, 1 completed. 3 Phase 2, 2 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 23Recruiting 2, Completed 1
Phase 12Completed 1, Recruiting 1

Follow CellCentric Ltd.: new trials by email

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
Inobrodib, Pomalidomide, Dexamethasone - Multiple Myeloma Refractory, Multiple Myeloma in Relapse
Phase 2RecruitingCellCentric Ltd.1002026-01-222026-09-21
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
CCS1477, Pomalidomide, Dexamethasone - Haematological Malignancy, Acute Myeloid Leukemia
Phase 1 / Phase 2RecruitingCellCentric Ltd.2502019-08-092026-06-24
Study to Evaluate CCS1477 in Advanced Tumours
CCS1477, Abiraterone acetate, Enzalutamide - Metastatic Castration-Resistant Prostate Cancer, Metastatic Breast Cancer
Phase 1 / Phase 2CompletedCellCentric Ltd.2192018-07-232026-09-25

Conditions studied

Breast Neoplasms (1)  ·  Carcinoma, Non-Small-Cell Lung (1)  ·  Hematologic Neoplasms (1)  ·  Leukemia, Myeloid, Acute (1)  ·  Lymphoma, Non-Hodgkin (1)  ·  Lymphoma, T-Cell, Peripheral (1)  ·  Multiple Myeloma (1)

Interventions

CCS1477 (3)  ·  Dexamethasone (2)  ·  pomalidomide (2)  ·  Abiraterone Acetate (1)  ·  Azacitidine (1)  ·  Bortezomib (1)  ·  Lenalidomide (1)  ·  atezolizumab (1)  ·  daratumumab (1)  ·  darolutamide (1)  ·  enzalutamide (1)  ·  ixazomib (1)  ·  olaparib (1)  ·  venetoclax (1)

Countries

United Kingdom (3)  ·  United States (3)  ·  France (2)  ·  Spain (2)  ·  Sweden (2)  ·  Netherlands (1)

Top investigators

Johann de Bono, MD (1)  ·  Naseer Qayum (1)  ·  Tim Somervaille (1)

Results publications

PMID 36125208, PMID 36826464